The “duty to warn” a patient’s family members about hereditary disease risks

The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis

Gideon Steinbach, Patrick M. Lynch, Robin Phillips et al. · New England Journal of Medicine · 2000 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +13

Risk-Reducing Salpingo-oophorectomy in Women with a<i>BRCA1</i>or<i>BRCA2</i>Mutation

Noah D. Kauff, Jaya M. Satagopan, Mark E. Robson et al. · New England Journal of Medicine · 2002 · 1.3K citations · Full text

Medicine, Gynecology, Oncology +17

Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer

H J Järvinen, Jukka‐Pekka Mecklin, P Sistonen · Gastroenterology · 1995 · 517 citations

Medicine, Genetics, Oncology +14

Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction

Daniel I. Chasman · JAMA · 2004 · 457 citations

Medicine, Pharmacology, Pharmacotherapy +16

Clinical Screening as Compared with DNA Analysis in Families with Multiple Endocrine Neoplasia Type 2A

Cornelis J.M. Lips, Rudy M. Landsvater, Jo W.M. Höppener et al. · New England Journal of Medicine · 1994 · 455 citations

Medicine, Genetics, Molecular Genetics +17